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	 The	 present	 work	 reports	 a	 reverse	 phase	 high	 performance	 liquid	 chromatography	 (RP‐
HPLC)	 method	 and	 high	 performance	 thin	 layer	 chromatography	 (HPTLC)	 method	 for	 the
simultaneous	 determination	 of	 febuxostat	 and	 diclofenac	 sodium	 in	 pharmaceutical	 dosage
form.	 HPLC	was	 performed	 using	 a	 Thermo	 Hypersil	 C18	 column	 (250	 ×	 4.6	mm	 i.d.,	 5	 μm
particle	 size)	 using	 a	 mixture	 of	 methanol:	 KH2PO4	 (0.02	 M)	 (70:30,	 v:v)	 as	 mobile	 phase.
Ultraviolet	 detection	 was	 carried	 out	 at	 280	 nm.	 The	 retention	 time	 of	 febuxostat	 and
diclofenac	sodium	were	found	to	be	6.725	and	8.892	min,	respectively.	The	HPTLC	separation
was	 conducted	 on	 Merck	 HPTLC	 aluminum	 sheets	 of	 silica	 gel	 60	 F254	 as	 stationary	 phase
using	 toluene:methanol	 in	 the	 ratio	 of	 7:3	 (v:v)	 as	 the	 mobile	 phase.	 The	 detection	 of
febuxostat	and	diclofenac	sodium	was	carried	out	at	297	nm.	The	Rf	values	of	febuxostat	and
diclofenac	 sodium	 were	 found	 to	 be	 0.48	 and	 0.60,	 respectively.	 Both	 the	 methods	 were
validated	 as	 per	 ICH	 guidelines.	 The	 proposed	 methods	 were	 found	 to	 be	 suitable	 for	 the
quantification	of	the	selected	combination	of	drugs	in	pharmaceutical	dosage	form.	
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1.	Introduction	
	
Febuxostat	 (FEB)	 is	 chemically	 known	 as	 2‐(3‐cyano‐4‐
isobutoxyphenyl)‐4‐methyl‐1,3‐thiazole‐5‐carboxylic	 acid	 [1].	
The	 chemical	 structure	 of	 febuxostat	 is	 shown	 in	 Figure	 1.	
Febuxostat	 is	 a	non‐purine	xanthine	oxidase	 inhibitor	used	 in	
the	 treatment	 of	 hyperuricaemia	 with	 chronic	 gout	 [2].	
Diclofenac	 (DIC)	 is	 chemically	 2‐(2,6‐dichloranilino)	phenyl	
acetic	acid	[1].	The	chemical	structure	of	diclofenac	is	shown	in	
Figure	 2.	 It	 is	 a	nonsteroidal	 anti‐inflammatory	 drug	(NSAID)	
taken	or	applied	to	reduce	inflammation	and	as	an	analgesic	for	
reducing	 pain	 in	 certain	 conditions	 [2].	 Literature	 review	
revealed	 that	 spectrophotometric	 method	 [3],	 HPLC	 methods	
[4‐7]	and	stability	indicating	studies	[8‐12]	have	been	reported	
for	 estimation	 of	 febuxostat	 and	 HPLC	 [13,14]	 and	 spectro‐
photometric	 [15‐17]	 methods	 have	 been	 reported	 for	
diclofenac	 alone.	 Further	 a	 validated	 HPLC	 method	 [18]	 for	
simultaneous	 estimation	 of	 febuxostat	 and	 diclofenac	
potassium	in	bulk	and	tablet	dosage	form	on	C18,	(250	mm	×	4.6	
mm	 ×	 5	 µm)	 column	 using	 acetonitrile:methanol:water	
(30:30:40,	v:v:v;	pH	adjusted	to	5.0	with	TEA	and	o‐phosphoric	
acid)	as	mobile	phase	and	validated	simultaneous	equation	and	
absorbance	 ratio	 methods	 [19,20]	 for	 the	 simultaneous	
estimation	 of	 febuxostat	 and	 diclofenac	 in	 tablet	 dosage	 form	
have	been	reported.	
	
 
	
Figure	1.	Structure	of	febuxostat.	
	
 
	
Figure	2.	Structure	of	diclofenac.	
	
In	 this	 work,	 a	 simple	 RP‐HPLC	 method	 using	 methanol:	
KH2PO4	 (0.02	 M)	 (70:30,	 v:v)	 as	 mobile	 phase	 and	 HPTLC	
method	 using	 toluene:methanol	 in	 the	 ratio	 of	 7:3	 (v:v)	 as	
mobile	phase	have	been	reported.		
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HPTLC	 is	 becoming	 a	 routine	 analysis	 technique	 due	 to	
advantages	of	low	operating	cost,	high	sample	throughput,	and	
need	 for	 minimum	 sample	 cleanup.	 The	 major	 advantage	 of	
HPTLC	is	that	several	samples	can	be	run	simultaneously	using	
a	 small	 quantity	 of	 mobile	 phase	 unlike	 HPLC,	 thus	 lowering	
analysis	time	and	cost	per	analysis.		
	
2.	Experimental	
	
2.1.	Instrumentation	
	
The	 HPLC	 system	 (Jasco	 Corporation,	 Tokyo,	 Japan)	
consisted	of	dual	Pump	(Model:	 Jasco	PU‐2080	Plus	and	 Jasco	
PU‐2087	 Plus	 Intelligent	 Prep.)	 along	 with	 manual	 injector	
sampler	programmed	at	20	µL	capacity	per	 injection.	The	UV/	
VIS	(Model:	Jasco	UV	2075)	detector	was	used.	LC	separations	
were	performed	on	a	Thermo	Hypersil	C18	column	(250	mm	×	
4.6	 mm	 i.d.,	 5	 μm	 particle	 size).	 Camag	 HPTLC	 system	 with	
Camag	 linomat	 IV	 automatic	 sample	 applicator,	 Camag	 TLC	
scanner	III	and	Camag	WinCATS	software	were	used	for	HPTLC	
method.	 Saturation	was	done	 in	Camag	Twin‐trough	 chamber	
(20	x	10	cm).	Merck	plates	coated	with	silicagel	60	F254	(250µm	
thickness)	on	aluminium	sheets	was	used	as	stationary	phase.		
	
2.2.	Reagents	and	chemicals	
	
Working	 standards	 of	 pharmaceutical	 grade	 FEB	 and	 DIC	
were	 obtained	 as	 gift	 samples	 from	 Centaur	 Pharmaceuticals	
Ltd.,	Pune.	The	tablet	XANFEB	DSR	containing	40	mg	FEB	and	
100	 mg	 DIC	 was	 procured	 from	 the	 local	 pharmacy.	 All	 the	
chemicals	 and	 reagents	 used	 were	 of	 HPLC	 grade	 obtained	
from	Merck	Ltd.,	Mumbai,	India.	
	
2.3.	Mobile	phase	
	
The	 mobile	 phase	 used	 in	 HPLC	 was	 methanol:	 KH2PO4	
(0.02	M)	(70:30,	v:v).	The	flow	rate	was	set	 to	1.0	mL/min.	 In	
HPTLC,	 toluene:methanol	 in	 the	 ratio	of	7:3	 (v:v)	was	used	as	
mobile	phase.		
	
2.4.	Preparation	of	standard	stock	solution	
	
Standard	 stock	 solution	 of	 FEB	 and	 DIC	 containing	 100	
μg/mL	 and	 1000	 ppm	 were	 prepared	 for	 HPLC	 and	 HPTLC	
methods,	 respectively.	 From	 the	 above	 stock	 solution,	
concentrations	 in	 the	 range	 of	 2‐12	 μg/mL	 of	 FEB	 and	 5‐30	
μg/mL	of	DIC	 for	HPLC	and	40‐280	ng/band	of	FEB	and	100‐
600	ng/band	of	DIC	 for	HPTLC	were	prepared.	The	peak	area	
for	the	different	concentrations	of	FEB	and	DIC	were	recorded.	
The	chromatogram	in	Figure	3	shows	the	retention	time	of	FEB	
and	DIC	as	6.725	and	8.892	min,	respectively,	by	HPLC	method.	
The	 calibration	 curves	 were	 constructed	 between	 concentra‐
tion	 against	 their	 respective	 peak	 area	 for	 FEB	 and	 DIC,	
respectively.	 Figure	 4	 shows	 the	UV	 overlay	 spectrum	 of	 FEB	
and	DIC	and	Figure	5	 represents	3‐D	Chromatogram	obtained	
in	 HPTLC	 study	 showing	 peaks	 of	 FEB	 and	 DIC	 in	 different	
concentrations.	 The	 densitogram	 of	 FEB	 and	DIC	 is	 shown	 in	
Figure	6.		
	
2.5.	Sample	preparation		
	
For	 analysis	 of	 the	 tablet	 dosage	 form,	 twenty	 tablets	
(XANFEB	DSR,	Indoco	Remedies	Ltd.)	containing	40	mg	of	FEB	
and	100	mg	of	DIC	were	weighed	individually	and	their	average	
weight	was	determined.		
For	 HPLC	 method,	 the	 tablets	 were	 crushed	 to	 a	 fine	
powder	and	powder	equivalent	to	the	weight	of	40	mg	of	FEB	
and	 100	 mg	 of	 DIC	 was	 transferred	 to	 a	 100	 mL	 volumetric	
flask	 and	 dissolved	 in	 about	 30	 mL	 of	 mobile	 phase.	 The	
solution	was	shaken	for	5	min	and	then	ultrasonicated	for	15‐
20	min	and	filtered	through	0.45	µm	Whatman	filter	paper.	The	
residue	 was	 washed	 with	 mobile	 phase	 and	 the	 combined	
filtrate	was	made	up	to	the	mark	with	the	same	solvent.	1	mL	of	
this	 solution	 was	 diluted	 to	 100	 mL	 solvent	 to	 get	 the	 final	
solution	 that	consists	of	concentration	of	4	μg/mL	of	FEB	and	
10	 μg/mL	 of	 DIC.	 The	 solution	 (20	 μL)	was	 then	 injected	 for	
quantitative	 analysis.	 The	 identities	 of	 both	 the	 compounds	
were	 established	 by	 comparing	 retention	 time	 of	 the	 sample	
solution	with	those	of	standard	mixed	solution.		
	
	
	
Figure	3.	Chromatogram	showing	Rt	of	FEB	and	DIC.
	
	
	
	
Figure	4.	UV	overlay	of	FEB	and	DIC.	
	
	
	
	
Figure	 5. 3‐D	 Chromatogram	 showing	 peaks	 of	 FEB	 and	 DIC	 in	 different
concentrations	at	297	nm.	
	
For	 HPTLC	method,	 quantity	 equivalent	 to	 40	mg	 of	 FEB	
and	100	mg	of	DIC	was	 taken	 in	100	mL	volumetric	 flask	and	
dissolved	in	40	mL	methanol	and	the	final	volume	was	made	up	
with	 the	same	solvent.	The	solution	was	 filtered	 through	0.45	
µm	nylon	syringe	filter.		
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Table	1.	Analysis	of	the	marketed	formulation	by	HPLC	and	HPTLC	methods	*.	
Drug	 HPLC	 HPTLC	
Amount	taken,	µg/mL	 Drug	content	(%)±S.D. %RSD Amount	taken,	ng/band Drug	content	(%)±S.D.	 %RSD
FEB	 4	 99.821±0.081	 0.019	 120	 99.68±0.018	 0.158	
DIC	 10	 100.190	±0.154	 0.055	 300	 99.21±0.134	 0.183	
*	n=6.	
	
	
Table	2.	Linear	regression	data	for	the	calibration	curves	by	HPLC	and	HPTLC	methods	a.	
Parameter	 HPLC	 HPTLC
FEB	 DIC	 FEB	 DIC	
Linearity	range	 2‐12	µg/mL	 5‐30	µg/mL 40‐280	ng/band 100‐600	ng/band
r2	 0.9997	 0.9997	 0.9989	 0.9999	
Slope	±	standard	error	 33170±268.3	 44490±385.2	 26.76±0.4507	 14.01±0.0663	
Intercept	±	standard	error	 3093±20.89	 1098±75.00	 209.47±70.22	 46.289±25.84	
Confidence	limit	of	slope	b	 32430	to	33920	 43420	to	45550 25.50±28.01 13.82±14.19	
Confidence	limit	of	intercept	b	 ‐2708	to	8893	 ‐19720	to	21920 14.55±404.4 ‐25.43±118.0	
Sy.x	c	 2244	 8057 75.42 27.75	
p	value	d	 <0.0001	 <0.0001 <0.0001 <0.0001	
a	n=6.	
b	95%	confidence	intervals.	
c	Standard	deviation	of	residuals	from	line.	
d	p	value	is	<	0.0001,	considered	highly	significant.		
		
	
Table	3.	Accuracy	studies	for	the	determination	of	FEB	and	DIC	by	HPLC	and	HPTLC	methods	*.	
Drug	 HPLC	
Amount	added	(%)	 Theoretical	content	(µg/mL) Measured	conc.±SD Recovery	(%)	 %	R.S.D
FEB	 80	 4.8	 4.85±	0.06 96.29	 1.212
100	 6	 6.05±0.02	 100.8	 0.399	
120	 7.2	 7.25	±	0.04 100.75	 0.687
DIC	 80	 12	 11.94	±	0.01	 99.5	 0.153	
100	 15	 14.94±0.08 99.6	 0.084
120	 18	 18.17±0.09 100.94	 0.094
Drug	 HPTLC	
Amount	added	(ng)	 Total	amount	(ng) Amount	recovered	(ng) Recovery	(%)	 %	R.S.D
FEB	 20	 60	 58.58	 97.64	 1.01	
40	 80	 81.52 101.9	 0.98
60	 100	 97.73	 97.73	 1.15	
DIC	 50	 150	 150.68 100.45	 1.16
100	 200	 197.86 98.93	 0.48
150	 250	 247.45 98.98	 1.37
*	n=6.	
	
	
From	 the	 resultant	 solution	 1	 mL	 was	 diluted	 to	 10	 mL	
which	contains	40	and	100	ppm	of	FEB	and	DIC	respectively.	3	
µL	 volume	 was	 spotted	 for	 six	 times	 to	 achieve	 a	 final	
concentration	 of	 120	 ng/band	 for	 FEB	 and	 300	 ng/band	 for	
DIC.	 The	 plate	 was	 developed	 in	 the	 previously	 described	
chromatographic	conditions	and	the	peak	area	of	the	spots	was	
measured	 at	 297	 nm.	 The	 results	 of	 analysis	 of	 marketed	
formulation	by	HPLC	and	HPTLC	methods	are	reported	in	Table	
1.	
	
2.6.	Validation		
	
The	 validation	 of	 an	 analytical	 method	 verifies	 that	 the	
characteristics	 of	 the	 method	 satisfy	 the	 requirements	 of	 the	
application	domain.	The	proposed	method	was	validated	in	the	
light	 of	 ICH	 Guidelines	 [21].	 The	 developed	 method	 was	
validated	 for	 linearity,	 accuracy,	 precision,	 repeatability,	
selectivity	 and	 specificity	 study	 as	 per	 ICH	 guidelines.	 All	 the	
validation	studies	were	carried	out	by	replicate	injection	of	the	
sample	and	standard	solutions.	
	
2.6.1.	Linearity	
	
Linear	relationship	was	observed	in	concentrations	ranging	
from	2‐12	μg/mL	for	FEB	and	5‐30	μg/mL	for	DIC	in	HPLC	and	
40‐280	 ng/band	 for	 FEB	 and	 100‐600	 ng/band	 for	 DIC	 in	
HPTLC.	 From	 the	 data	 obtained	 correlation	 coefficient,	 y‐
intercept	 and	 slope	 were	 calculated	 to	 provide	 mathematical	
estimates	of	the	degree	of	linearity	(Table	2).	
	
	
	
Figure	6. Densitogram	of	FEB	(0.48)	and	DIC	(0.60)	standard.
	
2.6.2.	Accuracy	
	
Accuracy	 of	 the	 developed	 methods	 was	 carried	 out	 by	
adding	 known	 amount	 of	 each	 drug	 corresponding	 to	 three	
concentration	 levels;	 80,	 100	 and	 120%	 of	 the	 label	 claim	 in	
HPLC	and	50,	100	and	150%	of	 the	 label	claim	in	HPTLC.	The	
accuracy	 was	 expressed	 as	 the	 percentage	 of	 analytes	
recovered	 by	 the	 assay	 methods.	 The	 results	 of	 percentage	
recovery	are	shown	in	Table	3.	
	
2.6.3.	Precision		
	
Precision	 was	 studied	 by	 repeatability	 and	 intermediate	
precision	studies.		
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Table	4.	Results	of	Precision	study	by	HPLC	and	HPTLC	methods	*.	
Drug	 HPLC	 HPTLC	
Drug	conc.	
(µg/mL)	
Repeatability	 Intermediate	precision Drug	conc.
(ng/band)	
Intraday	precision	 Interday	precision
Found	conc.	±	S.D.	 %	RSD	 Found	conc.	±	S.D. %	RSD %	RSD %	RSD
FEB	 2	 1.9394±0.0012	 0.065	 1.9312±0.0122	 0.632	 40	 1.42	 1.55	
6	 6.0677±0.0008	 0.013	 6.0816±0.0501 0.824 120 1.11 1.48	
12	 11.917±0.0043	 0.036	 11.8529±0.1297	 1.094	 240	 1.71	 1.71	
DIC	 5	 5.019±0.0307	 0.612	 5.1356±0.0985 1.919 100 1.53 1.002	
15	 14.898±0.0192	 0.128	 14.826±0.1184 0.798 300 0.121 1.53	
30	 30.7689±0.1954	 0.650	 29.9605±0.4040 1.348 600 0.434 0.625	
*	n=6.	
		
	
Table	5.	Limit	of	detection(LOD)	and	limit	of	quantitation(LOQ)	in	HPLC	and	HPTLC	methods.	
Parameter	 HPLC	 HPTLC	
FEB	 DIC FEB DIC	
LOD	 0.32	μg/mL 1.13	μg/mL 0.24	ng/band 0.13	ng/band	
LOQ	 0.98	μg/mL 2.87	μg/mL 0.70	ng/band 0.37	ng/band	
	
	
Table	6.	Robustness	evaluation	a	of	the	method	by	HPLC	(n	=	6).	
Factor	 Level	 Retention	time	(tR)	 Asymmetry	(T)	
FEB DIC FEB	 DIC
A:	Flow	Rate	(mL/min)	 	 	 	 	
	0.9	 ‐1	 6.712	 8.687	 1.02	 1.15	
	1.0	 	0	 6.725	 8.892	 1.01	 1.17	
	1.1	 +1 6.613 8.788 1.01	 1.16
B:	Percentage	of	methanol	in	the	mobile	phase	(v:v)	 	 	
	71	 ‐1	 6.712	 8.824	 1.33	 1.23	
	70	 	0	 6.725	 8.892	 1.31	 1.22	
	72	 +1	 6.798	 8.878	 1.29	 1.21	
C:	Columns	from	different	manufacturers	 	 	
	Hypersil	C18	column	 6.725	 8.892	 1.31	 1.22	
	HiQ‐Sil™	HS	C18	column	 6.798 8.811 1.32	 1.23
a	Average	of	three	concentrations	2,	6	and	12	µg/mL	for	FEB,	5,	15	and	30	µg/mL	for	DIC.	
	
	
Table	7.	Robustness	evaluation	of	the	method	by	HPTLC	(n	=	6).	
Parameter	 SD	of	peak	area	for	FEB %	RSD SD	of	peak	area	for	DIC	 %	RSD
Mobile	phase	composition	(±0.1	mL)	 15.26	 0.46	 22.77	 0.620	
Amount	of	mobile	phase	(±5%)	 11.51	 0.31	 16.53	 0.254	
Time	from	application	to	development	(+10	min)	 7.74	 0.25	 9.81	 0.240	
Time	from	development	to	scanning	(+10	min)	 14.63 0.45 7.38 0.154
	
	
The	 results	 are	 reported	 in	 terms	 of	 relative	 percentage	
standard	deviation	(%	RSD)	as	in	Table	4.	
	
2.6.4.	Limit	of	detection	(LOD),	and	limit	of	quantification	
(LOQ)	
	
The	lowest	amount	of	the	analyte	in	the	sample	which	can	
be	 detected	 and	 the	 lowest	 amount	 of	 analyte	 which	 can	 be	
quantitatively	 determined	 were	 studied	 and,	 LOD	 and	 LOQ	
values	are	reported	in	Table	5.	
	
2.6.5.	Robustness	
	
The	 robustness	 of	 the	 methods	 was	 determined	 by	
subjecting	 the	 methods	 to	 slight	 changes	 in	 the	 chromato‐
graphic	conditions.	 It	was	observed	that	there	was	no	marked	
change	 in	 the	 chromatogram	 which	 demonstrated	 that	 the	
methods	developed	are	robust	(Table	6	and	7).	
	
2.6.6	Selectivity		
	
The	 selectivity	 was	 checked	 by	 injecting	 the	 solution	 of	
both	the	drugs	into	the	HPLC	system	and	it	was	observed	that	
two	 sharp	 peaks	 of	 FEB	 and	 DIC	 having	 resolution	 of	 2.511	
were	 obtained	 at	 retention	 time	 of	 6.725	 and	 8.892	 min,	
respectively.	In	HPTLC,	the	Rf	values	of	FEB	and	DIC	were	found	
to	 be	 0.48	 and	 0.60,	 respectively.	 It	 was	 observed	 that	 the	
excipients	 did	 not	 interfere	 with	 the	 retention	 time	 and	 Rf	
values	 of	 the	 drugs.	 So,	 the	 methods	 developed	 for	 this	
combined	dosage	form	are	said	to	be	selective.	
	
2.6.7.	Specificity	
	
Specificity	 of	 the	method	was	 assessed	 by	 comparing	 the	
chromatograms	 obtained	 for	 standard	 drugs	 with	 the	
chromatogram	obtained	for	tablet	solution.	The	retention	time	
and	 Rf	 values	 of	 standard	 drugs	 and	 the	 drugs	 in	 sample	
solution	were	same,	so	the	methods	are	specific.	The	results	of	
system	suitability	parameters	in	HPLC	are	shown	in	Table	8.	
	
2.6.8.	Stability	of	analytical	solution	in	HPLC	
	
Stability	 of	 sample	 solution	was	 established	 by	 storage	 of	
sample	solution	at	ambient	temperature	for	48	hours.	FEB	and	
DIC	 sample	 solution	was	 re‐analyzed	 after	 24	 and	48	hr	 time	
intervals	 and	 assay	 value	 was	 determined	 and	 compared	
against	 fresh	 sample.	 Sample	 solution	 did	 not	 show	 any	
appreciable	 change	 in	 assay	 value	 when	 stored	 at	 ambient	
temperature	 up	 to	 48	 hr.	 It	 was	 found	 that	 the	 percentage	
labeled	amounts	of	FEB	at	0,	24	and	48 hr	were	99.8,	100.1	and	
100.5,	respectively	and	the	percentage	labeled	amounts	of	DIC	
were	100.1,	99.9	and	100.3,	respectively.	
	
3.	Results	and	discussion	
	
Column	chemistry,	solvent	type,	solvent	strength,	detection	
wavelength	 and	 flow	 rate	 were	 varied	 to	 determine	 the	
chromatographic	 conditions	 giving	 the	 best	 separation.	 The	
mobile	 phase	 conditions	 were	 optimized	 so	 that	 the	
components	 were	 free	 from	 the	 interference	 of	 solvent	 and	
excipients.		
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Table	8.	System	suitability	parameters	in	HPLC.	
Parameter	 FEB	 DIC	 Reference	values	
Theoretical	plates	(N)	 2216.17 2074 N	>	2000	
Peak	asymmetry	(T)	 1.01	 1.17 T	≤	2	
Capacity	factor	(K’)	 1.06	 1.61 1	<	K'	<	10	
HETP	(H)	a	 0.11	 0.12
Selectivity	(α)	b	 1.39	 Α	>	1	
Resolution	(Rs)	b	 2.511 Rs	≥	2	
a	HETP	(Height	Equivalent	to	Theoretical	Plate).	
b	With	respect	to	previous	peak.	
	
	
Mobile	 phase	 and	 flow	 rate	 selection	 was	 based	 on	 peak	
parameters	like	height,	area,	tailing,	theoretical	plates,	capacity	
factor,	resolution	and	run	time.	In	HPTLC,	the	effect	of	chamber	
saturation	 time	 on	 peak	 shapes,	 development	 pattern	 and	 Rf	
value	were	studied.	The	chamber	saturation	time	was	fixed	as	
30	min	as	the	Rf	value	and	resolution	were	satisfactory	for	FEB	
and	 DIC.	 Plate	 equilibration	 time	was	 fixed	 as	 20	min	 as	 the	
plates	 developed	 after	 20	 min	 of	 saturation	 showed	 good	
precision	 and	 reproducibility	 of	 peak	 area	 of	 drugs.	 The	
composition	 of	 solvent	 constituting	 the	 mobile	 phase	 was	
varied	 in	 order	 to	 study	 its	 effect	 on	 resolution	 of	 drugs.	 The	
analytes	 should	have	distinct	 retention	 time	 and	Rf	 values	 for	
good	resolution.	The	best	result	was	obtained	by	use	of	70:30	
(v:v)	 ratio	 of	 methanol	 and	 0.02	 M	 KH2PO4	 in	 HPLC	 and	
toluene:methanol	 in	 the	 ratio	 (7:3,	 v:v)	 in	 HPTLC.	 Under	 the	
optimum	 chromatographic	 conditions,	 the	 retention	 time	
obtained	 for	 FEB	 and	 DIC	 were	 6.725	 and	 8.892	 min,	
respectively,	 in	 HPLC	method	 and	 Rf	 values	 for	 FEB	 and	 DIC	
were	found	to	be	0.48	and	0.60,	respectively,	in	HPTLC	method.	
The	 values	 obtained	 for	 the	 validation	 parameters	 show	 that,	
the	chromatographic	conditions	are	appropriate	for	separation	
and	determination	of	the	compounds.	
	
4.	Conclusion	
	
A	 new	 RP	 HPLC	 method	 and	 HPTLC	 method	 have	 been	
developed	 for	 simultaneous	 analysis	 of	 Febuxostat	 and	
Diclofenac	 in	 combined	 dosage	 form.	 The	 developed	methods	
were	 found	 to	 be	 linear,	 accurate,	 reproducible,	 repeatable,	
precise,	 selective	 and	 specific	 proving	 the	 reliability	 of	 the	
methods.	 The	 recovery	 studies	 indicate	 that	 there	 was	 no	
interference	 of	 excipients.	 The	 proposed	 methods	 may	 be	
successfully	 applied	 to	 routine	 analysis	 of	 samples	 containing	
Febuxostat	and	Diclofenac.	
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